China's benchmark CSI 300 stockmarket index soared by 27% in 2020 thanks to the Covid-19-induced stimulus, but the rally peaked in February this year and the index has since tumbled by 13%. It has lost 4% since 1 January.
The main cause is tighter money, as Jacky Wong explains in The Wall Street Journal. The People’s Bank of China, the central bank, turned on the monetary taps last year in response to the virus. Yet with the recovery looking secure, it started to remove some of that liquidity from the financial system at the start of this year. “The spectre of bubbles past still haunt Chinese policy makers”: previous post-crisis stimulus efforts have saddled the financial system with a worrying debt burden. Regulators’ priority is curbing of speculation in property, but tighter credit brings “collateral damage” to stocks.
Big tech gets smaller
Chinese markets have also been affected by the ongoing global “rotation” away from highly-priced growth stocks (particularly technology companies) towards more cyclical sectors.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shares in tech giants such as Alibaba, Baidu and JD.com were “hammered” last week after US regulators pressed forward with changes that could ultimately see the firms removed from US stock exchanges, reports Arjun Kharpal for CNBC. Many Chinese tech firms have dual listings in America in order to access a wider pool of investor capital.
Big Chinese tech firms are also under pressure in their home market from tighter regulation. Beijing appears to have concluded that the sector needs to be cut down to size to ensure social stability, says Eoin Treacy on Fuller Treacy Money. “Companies like Tencent and Alibaba” now face clear “limits” on how much further they can expand.
The market pullback hasn’t undermined an ongoing boom in initial public offerings (IPOs), notes Hudson Lockett in the Financial Times. The value of flotations in Hong Kong has hit $16.4bn so far this year, compared with just $1.8bn in the first three months of last year. Yet Chinese stocks are not the value play they once were. The CSI 300’s price/earnings ratio has risen from 12 to 19 over the past year.
Tighter money in China underlines a growing split between rich economies, where central banks plan to keep credit easy, and emerging markets, where central bankers are growing hawkish; Russia and Brazil both recently raised interest rates. China was “first in, first out” of the pandemic, Peiqian Liu of Natwest Markets told Sofia Horta e Costa and Richard Frost on Bloomberg.
Now, this “stockmarket rout” could provide another leading indicator for the rest of the world: “When central banks and governments start exiting pandemic-era stimulus” the results for investors are “not pretty”.
-
Review: Trasierra – a yoga retreat in the Spanish hillsFlora Connell joins a yoga retreat at Trasierra, in the Sierra Morena mountains north of Seville
-
How much should I have in emergency savings?When your boiler breaks or your car won’t start, you can find yourself paying a hefty bill. How much should you have in emergency savings to cover unexpected costs?
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
